1. Home
  2. ARQT vs SFNC Comparison

ARQT vs SFNC Comparison

Compare ARQT & SFNC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ARQT
  • SFNC
  • Stock Information
  • Founded
  • ARQT 2016
  • SFNC 1903
  • Country
  • ARQT United States
  • SFNC United States
  • Employees
  • ARQT N/A
  • SFNC N/A
  • Industry
  • ARQT Biotechnology: Pharmaceutical Preparations
  • SFNC Major Banks
  • Sector
  • ARQT Health Care
  • SFNC Finance
  • Exchange
  • ARQT Nasdaq
  • SFNC Nasdaq
  • Market Cap
  • ARQT 2.1B
  • SFNC 2.2B
  • IPO Year
  • ARQT 2020
  • SFNC N/A
  • Fundamental
  • Price
  • ARQT $17.71
  • SFNC $20.37
  • Analyst Decision
  • ARQT Strong Buy
  • SFNC Hold
  • Analyst Count
  • ARQT 7
  • SFNC 3
  • Target Price
  • ARQT $19.00
  • SFNC $23.33
  • AVG Volume (30 Days)
  • ARQT 1.6M
  • SFNC 680.1K
  • Earning Date
  • ARQT 11-05-2025
  • SFNC 10-17-2025
  • Dividend Yield
  • ARQT N/A
  • SFNC 4.18%
  • EPS Growth
  • ARQT N/A
  • SFNC 6.86
  • EPS
  • ARQT N/A
  • SFNC 1.27
  • Revenue
  • ARQT $263,464,999.00
  • SFNC $742,875,000.00
  • Revenue This Year
  • ARQT $72.46
  • SFNC $26.29
  • Revenue Next Year
  • ARQT $31.69
  • SFNC $8.20
  • P/E Ratio
  • ARQT N/A
  • SFNC $16.01
  • Revenue Growth
  • ARQT 99.50
  • SFNC 2.18
  • 52 Week Low
  • ARQT $8.03
  • SFNC $17.20
  • 52 Week High
  • ARQT $18.15
  • SFNC $25.95
  • Technical
  • Relative Strength Index (RSI)
  • ARQT 63.97
  • SFNC 51.86
  • Support Level
  • ARQT $16.62
  • SFNC $19.57
  • Resistance Level
  • ARQT $18.15
  • SFNC $20.68
  • Average True Range (ATR)
  • ARQT 0.69
  • SFNC 0.38
  • MACD
  • ARQT 0.03
  • SFNC -0.12
  • Stochastic Oscillator
  • ARQT 85.57
  • SFNC 43.96

About ARQT Arcutis Biotherapeutics Inc.

Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.

About SFNC Simmons First National Corporation

Simmons First National Corp is a financial holding company. The company through its subsidiaries is engaged in providing banking services including consumer, real estate and commercial loans, checking, savings and time deposits. The company's loan portfolio comprises construction, single-family residential and commercial loans; non-real estate loans, nonaccrual and past due loans; and credit card loans, student loans and other consumer loans. It also offers various products and services such as trust services, investments, agricultural finance lending, equipment lending, insurance, consumer finance and small business administration lending. The business activity of the firm is functioned through the region of the United States.

Share on Social Networks: